Multimodality RV Phenotyping for Risk Stratification and Short-Term Outcomes in Group 1 PAH
Recruiting
Observational Study
Pulmonary Hypertension
Pulmonary Arterial Hypertension
Right Ventricular Function
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 50 (estimated)
- Sponsor
- Istanbul University - Cerrahpasa · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The MIRROR-PAH is a single-center, prospective, observational cohort study evaluating the incremental value of multimodality imaging-derived right ventricular characteristics for risk stratification in patients with Group 1 pulmonary arterial hypertension (PAH). The study aims to determine whether incorporation of echocardiographic and cardiac magnetic resonance (CMR)-derived right ventricular par…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adults aged 18 years or older
* Diagnosis of Group 1 pulmonary arterial hypertension (PAH) according to ESC/ERS guidelines
* Followed at the study center with a diagnosis of PAH
* Availability of right heart catheterization (RHC) and cardiac magnetic resonance (CMR) imaging da…
Contacts